Use of hydrogen sulfide synthesis inhibitors for cancer therapy
US10335382B2 · kind B2 · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 14, 2015 |
| Grant date | Jul 2, 2019 |
| Priority date | — |
| Expiry date | Dec 14, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/531
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain aspects the methods comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine-β-synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to a patient having a cancer associated with elevated production of hydrogen sulfide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.